BIOMM S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.77 BRL | +10.99% |
|
+8.62% | +207.44% |
| Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
| Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 390.4 | 753.4 | 1,098 | 879.7 | 551.9 | 469.8 |
| Enterprise Value (EV) 1 | 454.9 | 804.3 | 1,144 | 1,009 | 619.7 | 594.7 |
| P/E ratio | -8.14 x | -10.8 x | -14 x | -11 x | -5.37 x | -5.93 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 249 x | 84.2 x | 18.7 x | 8.21 x | 5.26 x | 3.98 x |
| EV / Revenue | 290 x | 89.9 x | 19.5 x | 9.42 x | 5.9 x | 5.03 x |
| EV / EBITDA | -13 x | -16.3 x | -24.7 x | -18 x | -8.1 x | -9.74 x |
| EV / FCF | -15.7 x | -21.5 x | -15.6 x | -15.1 x | -17.4 x | -12.2 x |
| FCF Yield | -6.36% | -4.65% | -6.42% | -6.64% | -5.74% | -8.23% |
| Price to Book | 3.68 x | 4.91 x | 5.73 x | 7.88 x | 3.47 x | 4.21 x |
| Nbr of stocks (in thousands) | 47,783 | 60,760 | 67,716 | 67,776 | 81,288 | 81,288 |
| Reference price 2 | 8.170 | 12.40 | 16.21 | 12.98 | 6.790 | 5.780 |
| Announcement Date | 3/28/19 | 3/27/20 | 3/26/21 | 3/25/22 | 3/23/23 | 3/27/24 |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.566 | 8.944 | 58.67 | 107.1 | 105 | 118.2 |
| EBITDA 1 | -35.03 | -49.38 | -46.37 | -56.05 | -76.46 | -61.04 |
| EBIT 1 | -36.67 | -52.61 | -55.3 | -65.65 | -86.24 | -72.52 |
| Operating Margin | -2,341.89% | -588.22% | -94.25% | -61.3% | -82.17% | -61.36% |
| Earnings before Tax (EBT) 1 | -42.53 | -55.77 | -70.7 | -79.79 | -93.19 | -80.8 |
| Net income 1 | -42.56 | -55.81 | -70.77 | -80.26 | -92.56 | -81.14 |
| Net margin | -2,717.88% | -624.02% | -120.62% | -74.95% | -88.19% | -68.65% |
| EPS 2 | -1.004 | -1.152 | -1.158 | -1.185 | -1.263 | -0.9751 |
| Free Cash Flow 1 | -28.94 | -37.41 | -73.41 | -66.94 | -35.55 | -48.92 |
| FCF margin | -1,847.73% | -418.26% | -125.13% | -62.51% | -33.88% | -41.39% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/28/19 | 3/27/20 | 3/26/21 | 3/25/22 | 3/23/23 | 3/27/24 |
1BRL in Million2BRL
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 64.5 | 50.9 | 46.2 | 129 | 67.7 | 125 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -1.84 x | -1.031 x | -0.9969 x | -2.302 x | -0.8858 x | -2.046 x |
| Free Cash Flow 1 | -28.9 | -37.4 | -73.4 | -66.9 | -35.6 | -48.9 |
| ROE (net income / shareholders' equity) | -51.5% | -43% | -41% | -53% | -68.4% | -57.7% |
| ROA (Net income/ Total Assets) | -8.07% | -9.47% | -8.39% | -10.2% | -13.9% | -12.1% |
| Assets 1 | 527.4 | 589.4 | 843.4 | 787.2 | 665.4 | 671.1 |
| Book Value Per Share 2 | 2.220 | 2.530 | 2.830 | 1.650 | 1.960 | 1.370 |
| Cash Flow per Share 2 | 0.3300 | 0.4900 | 0.8500 | 0.4600 | 0.9300 | 0.2900 |
| Capex 1 | 0.91 | 6.62 | 4.63 | 7.44 | 5.44 | 6.22 |
| Capex / Sales | 58.05% | 74% | 7.89% | 6.95% | 5.18% | 5.26% |
| Announcement Date | 3/28/19 | 3/27/20 | 3/26/21 | 3/25/22 | 3/23/23 | 3/27/24 |
1BRL in Million2BRL
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +207.44% | 310M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.75% | 22.18B | |
| -16.67% | 21.2B | |
| -8.86% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- BIOM3 Stock
- Financials Biomm S.A.
